Secretoneurin as a Novel Biomarker of Cardiovascular Episodes: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Jiří Plášek
,
Marie Lazárová
,
Jozef Dodulík
,
Patrik Šulc
,
David Stejskal
,
Zdeněk Švagera
,
František Všianský
,
Jan Václavík

Secretoneurin (SN) is a 33 amino-acid evolutionary conserved neuropeptide from the chromogranin peptide family. SN’s main effects may be cardioprotective and are believed to be mediated through its inhibition of calmodulin-dependent kinase II (CaMKII), which influences intracellular calcium handling. SN inhibition of CaMKII suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. This action may reduce the risk of ventricular arrhythmias and calcium-dependent remodelling in heart failure. SN is also involved in reducing the intracellular reactive oxygen species concentration, modulating the immune response, and regulating the cell cycle, including apoptosis. SN can predict mortality in different disease states, beyond the classical risk factors and markers of myocardial injury. Plasma SN levels are elevated soon after an arrhythmogenic episode. In summary, SN is a novel biomarker with potential in cardiovascular medicine, and probably beyond.

  • secretoneurin
  • ryanodine receptor
  • heart failure
  • arrhythmogenesis

1. Basic Properties of Secretoneurin

SN ranges from 31 (zebrafish) to 43 (lamprey) amino acids in length. SNs are evolutionarily conserved neuropeptides, mostly 33 (human, chicken, and frog) amino acids long, which arose in tetrapods, and they vary in very few positions [1]. All known SN peptides contain the YTPQ-X-LA-X(7)-EL sequence, which constitutes its central core [1]. In addition, SNa and SNb paralogs have been identified in teleosts, and the N-terminus and the middle of teleost SNa are identical to the mammalian sequence [2]. In contrast, teleost SNb, as compared to mammalian SNb, are only moderately conserved [2].
SN belongs to the secretogranin/chromogranin peptide family [1][2]. SN is produced by the proteolytic cleavage of a precursor protein, secretogranin II (SgII, also known as chromogranin C, 617 amino acids), which occurs in several tissues, including cardiomyocytes and neuroendocrine tissues [3]. SgII processing is known to be species- and tissue-specific; thus, sometimes larger SN immunoreactive fragments are generated, in addition to free SN. Most studies have supported the notion that the proprotein convertase subtilisin kexin-1 plays a central role in the generation of SN from SgII [4]. Exact sequence analysis of SgII can be found at https://www.uniprot.org/uniprotkb/P13521/entry#sequences (accessed on 1 December 2022).
Granin proteins are essential for protein sorting and hormone packaging in the regulated secretory pathway, where proteins cross the Golgi apparatus to the trans-Golgi network. Under acidic, high-calcium conditions, SgII may be processed by prohormone convertases in the secretory vesicle. Secretory vesicles that carry SN fuse with the cell membrane, and SN is released through calcium-dependent exocytosis. Once released from the cell, it binds to the SN receptor in an autocrine, paracrine, or neuroendocrine manner [5].

2. Biological Effects of Secretoneurin

In general, granins are predominantly known for their calcium-binding abilities. Granins have been extensively studied as neuroprotective factors and as co-factors of local immune and inflammatory reactions [6]. Before SN was identified as a potential biomarker of heart failure, acute coronary syndrome, and arrhythmogenesis, the prognostic values of chromogranin A and B were studied in similar conditions with variable results. In particular, chromogranin A is an independent predictor of long-term mortality and heart failure-related hospitalization in patients with acute coronary syndromes [7]. However, in patients with heart failure, chromogranin A did not show any additional value over contemporary markers [8]. In contrast, chromogranin B is up-regulated in chronic heart failure, and its plasma levels are correlated with disease severity [9].
SN has been detected in non-negligible amounts (range: 20–1500 pmol/L) in human serum, cerebrospinal fluid, and urine [10]. SN has also been detected in human dental pulp and afferent nerve fibres that are frequently associated with blood vessels [6][11]. SN immunoreactivity was also detected in the unmyelinated C-fibers which transmit predominantly nociceptive impulses [11]. All the biological effects of SN are not completely understood. The researchers can only speculate that the effects of SN may be exerted by SN receptors on the cell membrane. There is evidence that the SN receptor is a G-coupled membrane receptor [12]. In addition, SN may also act directly at different subcellular levels. The biological effects of SN are summarized in Figure 1.
Jcm 11 07191 g001 550
Figure 1. Intracellular signaling pathways of secretoneurin, and biological effects. ADP—adenosine diphosphate; AMP—adenosine monophosphate; AMPK—adenosine monophosphate kinase; ATP—adenosine triphosphate; cAMP—cyclic adenosine monophosphate; CaM—calmodulin; CaMKII—calmodulin-dependent kinase II; CSQ—calsequestrin; DAG—diacylglycerol; ERK—extracellular-regulated kinase; MAPK—mitogen-associated protein kinase; MEK—MAPK/ERK kinase; OX—oxidized; SOD—superoxide dismutase; PLB—phospholamban; P—phosphorus; PKA—protein kinase A; PKC—protein kinase C; PKG—protein kinase G; PLC -phospholipase C; RAF—serine-threonine protein kinase; ROS—reactive oxygen species; SN—secretoneurin; SNR—secretoneurin receptor.
In concentrations 10x the plasma concentration, SN inhibits CaMKII by 20–30%. SN exerts its effect by binding to calmodulin [13]. A direct effect, without binding to calmodulin, is thus again highly speculative. SN reduces ryanodine receptor (RyR)-mediated Ca2+ leakage by inhibiting RyR phosphorylation. This activity leads to a reduced risk of ventricular arrhythmia [14]. Furthermore, sarcoplasmic Ca2+ leakage leads to calmodulin calcification, which binds and activates CaMKII; thus, SN may also indirectly inhibit CaMKII at plasma concentrations that correspond to the levels observed in heart disease [14].For association of RyR function and risk of arrhythmia see Figure 2. 

Figure 2. Calcium handling/signalling in a ventricular cardiomyocyte illustrates the potential involvement of SN in arrhythmogenic risk, heart failure, and calcium-dependent remodelling

Interestingly, SN may also exert an anti-apoptotic effect on endothelial cells. This SN effect could be initiated by the activation of phosphoinositide-3 kinase/protein kinase B and the mitogen-associated protein kinase (MAPK) pathway [15]. In human umbilical vein endothelial cells, SN promoted proliferation and chemotaxis and reduced apoptosis [16]. In a myocardial infarction model, SN also acted as an endogenous stimulator of vascular endothelial growth factor and induced angiogenesis [17].
Of note, in animal models SN also enhances bone regeneration by increasing blood vessel and bone marrow formation [18].
In contrast to its beneficial roles, SN may also trigger the selective migration of monocytes and fibroblasts. This activity could potentially enhance inflammatory responses that lead to the acceleration of atherosclerosis [19].

3. Cellular Pathophysiology of Secretoneurin

Oxidative stress is a significant component of the cellular and subcellular processes that lead to inflammation and compensatory mechanisms, such as cell hypertrophy, fibrosis, and/or apoptosis. Reactive oxygen species (ROS) regulate mitogenic signal transduction in cardiomyocytes (evidenced in an animal experiment). Consequently, ROS may modulate hypertrophic signalling through MAPK pathways [20]. At the cellular and molecular levels, hypertrophic adaptions are quite complex in nature; they include paracrine, autocrine, and circulating biologically active effectors that react to many stimuli. Among these stimuli, the most important is wall stress [21].
Myocardial stretch triggers a chain of events: (1) the release of angiotensin II; (2) the release/formation of endothelin; (3) the activation of NADPH oxidase and transactivation of endothelium growth factor; (4) the production of mitochondrial ROS; (5) the activation of redox-sensitive kinases; (6) an increase in the intracellular sodium concentration; and (7) a transient increase in the Ca2+ amplitude through the Na+/Ca2+ exchanger. SN was found to attenuate isoproterenol-induced myocardial cell hypertrophy by suppressing ROS production and inducing the activities of superoxide dismutase and catalase [22]. These effects are known to be mediated by adenosine-monophosphate or the extracellular-regulated kinase (ERK)/MAPK pathway. It is less probable that SN directly affects myocardial cell hypertrophy [18]. Nevertheless, SN gene therapy (in an animal model of isoproterenol-induced hypertrophy) led to significant reductions in natriuretic peptide levels, the heart-weight to body-weight ratio, and surprisingly, interstitial fibrosis [23].
Other results have indicated that SN, both acutely and after prolonged exposure, induced the augmented expression of endothelial nitric oxide synthase and calmodulin [23]. In this respect, SN may play a protective role in ischaemic heart disease by enhancing endothelium-dependent relaxation. Endothelium-dependent relaxation may also involve the activation of cyclooxygenase, which would lead to the production of prostacyclin [23].
SN may be implicated in the inflammatory response, because it modulates leukocytes, endothelial cells, and mesenchymal cells. SN promotes transendothelial leukocyte migration and adhesion; this activity is comparable to that promoted by tumour necrosis factor alpha [24]. In response to injury, SN stimulates an increase in the migration and locomotion of human monocytes [25]. In endothelium, SN activates the G-protein-coupled and protein kinase C-mediated signalling pathways. As a result, the cytoplasmatic calcium concentration rises [24]. SN also inhibits the tight junctions between endothelial cells, which increases their permeability [26]. Plasma SN concentrations that led to endothelium-derived relaxation in vitro were higher than those detected in humans with hypoxic conditions [27][28]. However, plasma SN concentrations may not precisely reflect the tissue (endothelium) concentration. The most common pathological conditions that lead to increases in SN expression are the growth of active, predominantly neuroendocrine tumours and hypoxia [9][29].

This entry is adapted from the peer-reviewed paper 10.3390/jcm11237191

References

  1. Trudeau, V.L.; Martyniuk, C.J.; Zhao, E.; Hu, H.; Volkoff, H.; Decatur, W.A.; Basak, A. Is secretoneurin a new hormone? Gen. Comp. Endocrinol. 2012, 175, 10–18.
  2. Zhao, E.; Hu, H.; Trudeau, L.V. Secretoneurin as a hormone regulator in the pituitary. Regul. Pept. 2010, 165, 117–122.
  3. Kirchmair, R.; Hogue-Angeletti, R.; Gutierrez, J.; Fischer-Colbrie, R.; Winkler, H. Secretineurin: A neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin II (chromogranin C). Neuroscience 1993, 53, 359–365.
  4. Zhao, E.; Basak, A.; Crump, K.; Trudeau, V.L. Proteolytic processing and differential distribution of secretogranin-II in goldfish. Gen. Comp. Endocrinol. 2006, 146, 100–107.
  5. Morvan, J. Tooze SA. Discovery and progress in our understanding of the regulated secretory pathway in neuronedocrine cells. Histochem. Cell Biol. 2008, 129, 243–252.
  6. Pertl, C.; Kaufmann, W.; Amann, R.; Heinemann, A.; Ebeleseder, K.; Polansky, R.; Kim, S. Secretoneurin, a novel neuropeptide, in the human dental pulp. Arch. Oral Biol. 1998, 43, 361–365.
  7. Jansson, A.M.; Røsjø, H.; Omland, T.; Karlsson, T.; Hartford, M.; Flyvbjerg, A.; Caidahl, K. Prognostic value of circulation chromogranin A levels in acute coronary syndromes. Eur. Heart J. 2009, 30, 25–32.
  8. Røsjø, H.; Masson, S.; Latini, R.; Flyvbjerg, A.; Milani, V.; La Rovere, M.T.; Revera, M.; Mezzani, A.; Tognoni, G.; Tavazzi, L.; et al. Prognostic value of chromogranin A in chornic heart failure: Data from the GISSI-Heart failure trial. Eur. Heart J. Fail. 2010, 12, 549–556.
  9. Røsjø, H.; Husberg, C.; Dahl, M.B.; Stridsberg, M.; Sjaastad, I.; Finsen, A.V.; Carlson, C.R.; Øie, E.; Omland, T.; Christensen, G. Chromogranin B in heart failure: A putative cardiac biomarker expressed in the failing myocardium. Circ. Heart Fail. 2010, 3, 503–511.
  10. Fischer-Colbrie, R.; Kirchmair, R.; Kahler, C.M.; Wiedermann, C.J.; Saria, A. Secretoneurin: A new player in angiogenesis and chemotaxis linking nerves, blood vessels and the immune system. Curr. Pept. Sci. 2005, 6, 373–385.
  11. Steiner, R.; Colbrie-Fischer, R.; Bletsa, A.; Laimer, J.; Troger, J. Secretoneurin and PE-11 immunoreactivity in the human dental pulp. Arch. Oral Biol. 2018, 86, 13–17.
  12. Mitchell, K.; Mikwar, M.; Da Fonte, D.; Lu, C.; Tao, B.; Peng, D.; Erandani, W.U.; Hu, W.; Trudeau, V.L. Secretoneurin is a secretogranin-2 derived hormonal peptide in vertebrate neuroendocrine systems. Gen. Comp. Endocrinol. 2020, 299, 113588.
  13. Ottesen, A.H.; Louch, W.E.; Carlson, C.R.; Landsverk, O.J.; Kurola, J.; Johansen, R.F.; Moe, M.K.; Aronsen, J.M.; Høiseth, A.D.; Jarstadmarken, H.; et al. Secretoneurin is a novel prognostic cardiovascular biomarker associated with cardiomyocyte calcium handling. J. Am. Coll. Cardiol. 2015, 65, 339–351.
  14. Ottesen, A.H.; Carlson, C.R.; Eken, O.S.; Sadredini, M.; Myhre, P.L.; Shen, X.; Dalhus, B.; Laver, D.R.; Lunde, P.K.; Kurola, J.; et al. Secretoneurin is an Endogenous CaMKII Inhibitor that Attenuates Ca2+-Dependent Arrhythmia. Circ. Arrhythm. Electrophysiol. 2019, 12, 007045.
  15. Kirchmair, R.; Gander, R.; Egger, M.; Hanley, A.; Silver, M.; Ritsch, A.; Murayama, T.; Kaneider, N.; Sturm, W.; Kearny, M.; et al. The neuropeptide secretoneurin acts as a direct angiogenic cytokine in vitro and in vivo. Circulation 2004, 109, 777–783.
  16. Schgoer, W.; Theurl, M.; Albrecht-Schgoer, K.; Jonach, V.; Koller, B.; Lener, D.; Franz, W.M.; Kirchmair, R. Secretoneurin gene therapy improves blood flow in an ischemia model in type 1 diabetic mice by enhancing therapeutic neovascularization. PLoS ONE 2013, 8, e74029.
  17. Albrecht-Schgoer, K.; Schgoer, W.; Holfeld, J.; Theurl, M.; Wiedemann, D.; Steger, C.; Gupta, R.; Semsroth, S.; Fischer-Colbrie, R.; Beer, A.G.; et al. The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells. Circulation 2012, 126, 2491–2501.
  18. Assefa, F.; Lim, J.; Kim, J.A.; Ihn, H.J.; Lim, S.; Nam, S.H.; Bae, Y.C.; Park, E.K. Secretoneurin, a neuropeptide, enhances bone regeneration in a mouse calcarial bone defect model. Tissue Eng. Regen. Med. 2021, 18, 315–324.
  19. Kahler, C.M.; Schratzberger, P.; Wiedermann, C.J. Response of vascular smooth muscle cells to the neuropeptide secretoneurin. A functional role for migration and proliferation in vitro. Arter. Thromb. Vasc. Biol. 1997, 17, 2029–2035.
  20. Tanaka, K.; Honda, M.; Takabate, T. Redox regulation of MAPK pathways and cardiac hypertrophy in adult rat cardiac myocyte. J. Am. Coll. Cardiol. 2001, 37, 676–685.
  21. Cingolani, H.E.; Ennis, I.L.; Aiello, E.A.; Pérez, N.G. Role of autocrine/paracrine mechanisms in response to myocardial strain. Pflug. Arch. 2011, 462, 29–38.
  22. Chen, H.-L.; Liu, Y.; Jiang, W.; Wang, X.-X.; Yuan, G.-L.; Zhao, Y.-L.; Yu, C. Secretoneurin suppresses cardiac hypertrophy through suppression of oxidant stress. Eur. J. Pharmacol. 2018, 822, 13–24.
  23. Chan, C.K.Y.; Vanhoutte, P.M. Secretoneurin facilitates endothelium-dependent relaxations in porcine coronary arteries. Am. J. Physiol. Circ. Physiol. 2011, 300, H1159–H1165.
  24. Kähler, C.M.; Schratzberger, P.; Kaufmann, G.; Hochleitner, B.; Bechter, O.; Götsch, C.; Wöll, E.; Marschang, P.; Herold, M.; Wiedermann, C.J. Transendothelial migration of leukocytes and signaling in response to neuropeptide secretoneurin. Regul. Pept. 2002, 105, 35–46.
  25. Reinisch, N.; Kirchmair, R.; Kähler, C.M.; Hogue-Angeletti, R.; Fischer-Colbrie, R.; Winkler, H.; Wiedermann, C.J. Attraction of human monocytes by the neuropeptide secretoneurin. FEBS Lett. 1993, 334, 41–44.
  26. Zhao, E.; Zhang, D.; Basak, A.; Trudeau, V.L. New insights into granin-derived peptides: Evolution and endocrine roles. Gen. Comp. Endocrinol. 2009, 164, 161–174.
  27. Ischia, R.; Gasser, R.W.; Fischer-Colbrie, R.; Eder, U.; Pagani, A.; Cubeddu, L.X.; Lovisetti-Scamihorn, P.; Finkenstedt, G.; Laslop, A.; Winkler, H. Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients. J. Clin. Endocrinol. Metab. 2000, 85, 355–360.
  28. Stridsberg, M.; Eriksson, B.; Janson, E.T. Measurement of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours. Regul. Pept. 2008, 148, 95–98.
  29. Taupenot, L.; Harper, K.L.; O’Connor, D.T. The chromogranin-secretogranin family. N. Engl. J. Med. 2003, 348, 1134–1149.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
ScholarVision Creations
Feedback